Literature DB >> 16669621

Major groove interactions of vaccinia Topo I provide specificity by optimally positioning the covalent phosphotyrosine linkage.

Rajesh Nagarajan1, James T Stivers.   

Abstract

Vaccinia DNA topoisomerase (vTopo) is a prototypic eukaryotic type I topoisomerase that shows high specificity for nucleophilic substitution at a single phosphodiester linkage in the pentapyrimidine recognition sequence 5'-(C/T)+5 C+4 C+3 T+2 T+1 p / N(-1). This reaction involves reversible transesterification where the active site tyrosine of the enzyme and a 5'-hydroxyl nucleophile of DNA compete for attack at the phosphoryl group. The finite lifetime of the covalent phosphotyrosine adduct allows the enzyme to relax multiple supercoils by rotation of the 5'-OH strand before the DNA backbone is religated. To dissect the nature of the unique sequence specificity, subtle modifications to the major groove of the GGGAA 5'-sequence of the nonscissile strand were introduced and their effects on each step of the catalytic cycle were measured. Although these modifications had no effect on noncovalent DNA binding (K(D)) or the rate of reversible DNA cleavage (k(cl)), significant decreases in the cleavage equilibrium (K(cl) = k(cl)/k(r)) arising from increased rates of 5'-hydroxyl attack (k(r)) at the phosphotyrosine linkage were observed. These data and other findings support a model in which major groove interactions are used to position the phosphotyrosine linkage relative to the mobile 5'-hydroxyl nucleophile. In the absence of native sequence interactions, the phosphotyrosine has a higher probability of encountering the 5'-hydroxyl nucleophile, leading to an enhanced rate of ligation and a diminished equilibrium constant for cleavage. By this unusual specificity mechanism, the enzyme prevents formation of stable covalent adducts at nonconsensus sites in genomic DNA.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16669621      PMCID: PMC2515098          DOI: 10.1021/bi060133i

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  19 in total

1.  Individual nucleotide bases, not base pairs, are critical for triggering site-specific DNA cleavage by vaccinia topoisomerase.

Authors:  Ligeng Tian; Jane M Sayer; Donald M Jerina; Stewart Shuman
Journal:  J Biol Chem       Date:  2004-07-13       Impact factor: 5.157

2.  Site-specific interaction of vaccinia virus topoisomerase I with duplex DNA. Minimal DNA substrate for strand cleavage in vitro.

Authors:  S Shuman
Journal:  J Biol Chem       Date:  1991-10-25       Impact factor: 5.157

3.  Site-specific DNA cleavage by vaccinia virus DNA topoisomerase I. Role of nucleotide sequence and DNA secondary structure.

Authors:  S Shuman
Journal:  J Biol Chem       Date:  1991-01-25       Impact factor: 5.157

Review 4.  DNA topoisomerase poisons as antitumor drugs.

Authors:  L F Liu
Journal:  Annu Rev Biochem       Date:  1989       Impact factor: 23.643

5.  Fluorescence spectroscopy studies of vaccinia type IB DNA topoisomerase. Closing of the enzyme clamp is faster than DNA cleavage.

Authors:  Keehwan Kwon; James T Stivers
Journal:  J Biol Chem       Date:  2001-10-31       Impact factor: 5.157

6.  19F NMR studies of vaccinia type IB topoisomerase. Conformational dynamics of the bound DNA substrate.

Authors:  Keehwan Kwon; Yu Lin Jiang; Fenhong Song; James T Stivers
Journal:  J Biol Chem       Date:  2001-10-31       Impact factor: 5.157

7.  Specific DNA cleavage and binding by vaccinia virus DNA topoisomerase I.

Authors:  S Shuman; J Prescott
Journal:  J Biol Chem       Date:  1990-10-15       Impact factor: 5.157

8.  Site-specific DNA transesterification by vaccinia topoisomerase: role of specific phosphates and nucleosides.

Authors:  C Cheng; S Shuman
Journal:  Biochemistry       Date:  1999-12-14       Impact factor: 3.162

9.  Remote phosphate contacts trigger assembly of the active site of DNA topoisomerase IB.

Authors:  Ligeng Tian; Christopher D Claeboe; Sidney M Hecht; Stewart Shuman
Journal:  Structure       Date:  2004-01       Impact factor: 5.006

10.  Site-specific DNA transesterification by vaccinia topoisomerase: effects of benzo[alpha]pyrene-dA, 8-oxoguanine, 8-oxoadenine and 2-aminopurine modifications.

Authors:  Lyudmila Yakovleva; Ligeng Tian; Jane M Sayer; Govind P Kalena; Heiko Kroth; Donald M Jerina; Stewart Shuman
Journal:  J Biol Chem       Date:  2003-08-08       Impact factor: 5.157

View more
  6 in total

1.  Unmasking Anticooperative DNA-binding interactions of vaccinia DNA topoisomerase I.

Authors:  Rajesh Nagarajan; James T Stivers
Journal:  Biochemistry       Date:  2007-01-09       Impact factor: 3.162

2.  Chemical and traditional mutagenesis of vaccinia DNA topoisomerase provides insights to cleavage site recognition and transesterification chemistry.

Authors:  Lyudmila Yakovleva; Shengxi Chen; Sidney M Hecht; Stewart Shuman
Journal:  J Biol Chem       Date:  2008-03-25       Impact factor: 5.157

3.  Mechanism and specificity of DNA strand exchange catalyzed by vaccinia DNA topoisomerase type I.

Authors:  Mary R Stahley; James T Stivers
Journal:  Biochemistry       Date:  2010-04-06       Impact factor: 3.162

4.  Highly efficient production of soluble proteins from insoluble inclusion bodies by a two-step-denaturing and refolding method.

Authors:  Zhong Yang; Linlin Zhang; Yan Zhang; Ting Zhang; Yanye Feng; Xiuxiu Lu; Wenxian Lan; Jufang Wang; Houming Wu; Chunyang Cao; Xiaoning Wang
Journal:  PLoS One       Date:  2011-07-29       Impact factor: 3.240

5.  Chemical mutagenesis of vaccinia DNA topoisomerase lysine 167 provides insights to the catalysis of DNA transesterification.

Authors:  Lyudmila Yakovleva; Stewart Shuman
Journal:  Biochemistry       Date:  2013-01-23       Impact factor: 3.162

6.  Characterization of DNA Binding by the Isolated N-Terminal Domain of Vaccinia Virus DNA Topoisomerase IB.

Authors:  Benjamin Reed; Lyudmila Yakovleva; Stewart Shuman; Ranajeet Ghose
Journal:  Biochemistry       Date:  2017-06-19       Impact factor: 3.162

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.